334157
Prevalence and determinants of contraceptive use in a nationally representative sample of women aged 18-24 in the US
Methods: Using a subsample of the 2011-2013 National Survey of Family Growth (n=699), we estimated the prevalence of contraceptive use for young women at risk of unwanted/unplanned pregnancy. We used ordinal logistic regression to identify determinants of being on more effective forms of contraception. Appropriate sample weights were applied.
Results: 47.0% of respondents used short-term hormonal contraceptives, 22% used barrier methods, 18% used no contraception, 10% used LARC, and 4% used withdrawal. After controlling for covariates, being in college (p=.011), privately insured (p=.015), non-Hispanic white (p=.006), having children (p=.003), and receiving contraceptive counseling (p<.001) conferred higher odds of being on more effective contraception.
Conclusion: Structural issues and access to services appear to influence utilization of more effective contraceptive methods. It is essential that young women have access to affordable reproductive health services. Interventions should address access to care, particularly for those who are at risk of unwanted pregnancy. Educational and social policies should support women’s autonomy in their reproductive decision-making.
Learning Areas:
Advocacy for health and health educationPlanning of health education strategies, interventions, and programs
Public health or related education
Public health or related research
Social and behavioral sciences
Learning Objectives:
Describe the prevalence of contraceptive method use among women aged 18-24 years
Discuss the association between between contraceptive method choice and socio-demographic, fertility-related, and other variables.
Keyword(s): Contraception, Family Planning
Qualified on the content I am responsible for because: I initiated the project, contributed to the design of the study, and completed the data analysis.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.